Drummand M, Members of the ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems, Ronquest N. A case of multitasking: conducting and using HTA and HEOR in pluralistic healthcare systems. Value & outcomes spotlight. 2022 Jul;8(4):7-9.
Song W, Musetti SN, Huang L. Nanomaterials for cancer immunotherapy. Biomaterials. 2017 Dec;148:16-30. doi: 10.1016/j.biomaterials
Luo C, Miao L, Zhao Y, Musetti S, Wang Y, Shi K, Huang L. A novel cationic lipid with intrinsic antitumor activity to facilitate gene therapy of TRAIL DNA. Biomaterials. 2016 Sep;102:239-48. doi: 10.1016/j.biomaterials.2016.06.030
Wolowacz SE. Task force recommendations on the collection of health-state utility data in clinical studies: an interview with Sorrel E. Wolowacz, PhD, Co-Chair, on good practices for Outcomes Research Task Force. Value & outcomes spotlight. 2016 Sep;2(5):22-3.
Goyal RK, Patel JG, Sansgiry SS. Pharmacists perceptions of drug reimbursement rates and processing times among managed care plans. Drug benefit trends: a publication for manager and health professionals in hmos and ppos. 2010;22(4):116-20.
Allan JS, Kanda P, Kennedy RC, Cobb EK, Anthony MS, Eichberg JW. Isolation and characterization of simian immunodeficiency virus from two subspecies of African green monkeys. Aids Res Hum Retrovir. 1990 Mar;6(3):275-85.